![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 19, 2021 6:18:23 PM
Thanks for the reminder on the adjuvant trial.
I have to say that that one stopped recruiting about six years ago.
And I think we had any results that we are likely to get some considerable time back. It's those 23 patients again...
The question about how important is the addition of Poly-ICLC or Imiquimod adjuvants is not really answered for me, though they may augment a treatment response.
Anyway the P3 did without.
But they could conceivably be used anyway off-label on an individual level, as both already have an approval.
I'm not so sure that they do have a pretty good idea as to who responds best to L, other than the already very apparent meth/unmeth difference. How could they? Or they might have some idea, but simply not have had the opportunity to test. For example; L without TMZ for unmeth might work better and would prevent the TMZ-induced mutational shift.
My hypothesis which is really based on nothing tangible, is that some of the UCLA guys are caught up in the 'combo is best' mantra.
Apart from anything else, such a combo would be putting the price tag up to close on $0.5M...
And surely we are not sufficiently taking into account the consistent failure to date of ICI's in brain cancer, and the HPD, auto-immune dysfunction and adaptive resistance associated with ICIs in other cancers!
My supposition is that Rob Prins is the primary enthusiast for the combo with an ICI.
Before anyone shoots me down, this is just a personal current hypothesis.
If future info or data sheds more light, and proves me wide of the mark, I'll amend my hypothesis accordingly!
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM